MedTrace Logo

Metastatic Solid Cancer Clinical Trial

NCT04739618 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-07-23

No results posted yet for this study

Summary

This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.

Conditions

Interventions

DRUG

Keytruda Injectable Product

PD-1 inhibitor antibody

DRUG

Yervoy Injectable Product

Anti-CTLA-4 antibody

DRUG

GM-CSF

1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.

PROCEDURE

Non-ablative Cryosurgical freezing

To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.

Sponsors & Collaborators

  • ImmunSYS, LLC

    lead OTHER

Principal Investigators

  • Gary Onik, M.D. · ImmunSYS, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-04
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04739618 on ClinicalTrials.gov